Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Guidance

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Earnings Beats
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Reiteration
  • Trading Ideas

Analyst Views West Pharmaceutical’s Q4 Earnings Impressive Despite Headwinds

By Vandana Singh
February 16, 1:48 PM
West Pharmaceutical Services Inc (NYSE:WST) reported Q4 2022 net sales of $708.7 million, down 3%, and organic net sales growth…

WST

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • News

Hyatt Hotels Says Optimistic About The Year Ahead Post Solid Q4 Results

By Shivani Kumaresan
February 16, 1:11 PM
Hyatt Hotels Corp (NYSE:H) reported fourth-quarter FY22 sales of $1.58 billion, beating the consensus of $1.52 billion. Comparable system-wide RevPAR…

H

Read More
2 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • Earnings
  • Earnings Beats
  • General
  • Guidance
  • Health Care
  • Large Cap
  • Movers
  • News
  • Price Target
  • Trading Ideas

Analysts Are Bullish On Seagen’s Catalyst-Rich Pipeline, Finding No Problem With No M&A

By Vandana Singh
February 16, 12:48 PM
Seagen Inc (NASDAQ:SGEN) reported a Q4 EPS loss of $(0.80), better than the consensus of $(1.05) and $(0.95) a year…

SGEN

Read More
1 minute read
  • Guidance
  • Management
  • News

GM CEO Says This Year Will Be The Year GM Pulls Away From Traditional Automakers

By Happy Mohamed
February 16, 12:23 PM
- Wolfe Conf.

GM

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Earnings
  • Earnings Beats
  • General
  • Guidance
  • Health Care
  • Movers
  • News
  • Trading Ideas

Analyst Says Henry Schein 2023 Guidance Encouraging But Still Impacted By Headwinds

By Vandana Singh
February 16, 12:05 PM
Henry Schein Inc (NASDAQ:HSIC) posts Q4 FY22 sales of $3.37 billion, beating the consensus of $3.34 billion. The 1.2% increase…

HSIC

Read More
1 minute read
  • Guidance
  • News

Hasbro Expects 1H Revenue To Be Down About 20% From Last Year, With Q1 Revenue Down About 25%

By Bill Haddad
February 16, 10:24 AM
-Reuters

HAS

Read More
1 minute read
  • Earnings
  • General
  • Guidance
  • Large Cap
  • News

Airbus Expects Higher Plane Deliveries For 2023, But Cautious On Production For A320

By Vandana Singh
February 16, 9:10 AM
Airbus SE’s (OTC:EADSY) (OTC:EADSF) FY22 revenues increased 13% Y/Y to €58.8 billion. Revenues generated by Airbus’ commercial aircraft activities increased by…

EADSF

Read More
1 minute read
  • Guidance
  • News

Labcorp FY23 Adj. EPS Outlook $16.00 – $18.00 Vs. $17.71 Estimate, Free Cash Flow $1.0B – $1.2B

By Benzinga Newsdesk
February 16, 8:11 AM
2023 Guidance The following guidance assumes foreign exchange rates effective as of Dec. 31, 2022, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital

LH

Read More
1 minute read
  • Guidance
  • News

Visteon FY23 Outlook: Revenue $3.95B – $4.15B Vs. $3.93B Estimate, EBITDA $405 – $445M, FCF $115M – $165M

By Benzinga Newsdesk
February 16, 7:59 AM
Robust Growth in 2022 and Strong Outlook for 2023 "The Visteon team had a strong finish to round out a successful 2022, again achieving market out-performance along with 45 new program launches and $6 billion in

VC

Read More
1 minute read
  • Earnings
  • Guidance
  • News

Henry Schein Expects FY23 Adjusted EPS of $5.25-$5.42 Vs. 4.95 Estimate

By Benzinga Newsdesk
February 16, 7:35 AM
2023 sales growth is expected to be approximately 1% to 3% over 2022. 2023 sales of PPE products and COVID-19 test kits are expected to decrease in aggregate by

HSIC

Posts pagination

Previous 1 … 489 490 491 … 637 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service